Summary
Boston Scientific Corporation (BSX) has filed an 8-K report on October 23, 2024, primarily announcing its financial results for the third quarter ended September 30, 2024. The key information for investors is contained within the press release furnished as Exhibit 99.1 to this filing. This press release details the company's performance during the quarter, providing crucial data on revenue, profitability, and potentially other key financial and operational metrics that will inform investor understanding of the company's current standing and future outlook. Investors should review the press release (Exhibit 99.1) for specific details regarding BSX's third-quarter performance, including any updates to forward-looking guidance. The 8-K filing itself serves as a notification mechanism for the availability of this earnings information, which is critical for assessing the company's financial health, operational execution, and progress against its strategic objectives. The information presented in the press release is furnished and not deemed "filed" for certain regulatory purposes, a standard disclosure for such announcements.
Key Highlights
- 1Boston Scientific Corporation (BSX) announced its financial results for the third quarter ended September 30, 2024.
- 2The detailed financial results are provided in a press release, furnished as Exhibit 99.1 to the 8-K filing.
- 3Investors are directed to the press release for specific performance metrics and financial condition details.
- 4The filing indicates the event date of the announcement was October 22, 2024, with the filing date being October 23, 2024.
- 5Information furnished in Item 2.02 and Exhibit 99.1 is not considered 'filed' for Section 18 of the Exchange Act or other liabilities.
- 6The 8-K also includes the cover page Interactive Data File (XBRL).